U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff November 2020

Download the Final Compliance Policy Guide (CPG)
Final
Docket Number:
FDA-2019-D-3904
Issued by:
Guidance Issuing Office
Office of Inspections and Investigations

Introduction

The purpose of this Compliance Policy Guide (CPG) is to provide guidance to FDA staff and trade regarding requests to the FDA, for a preliminary admissibility assessment of FDA-regulated products that would be included in a weekly entry filing (WEF).  The FDA recommends that persons who wish to file a weekly entry with the U.S. Customs and Border Protection (CBP) under 19 CFR 146.63(c)(1), request a preliminary admissibility assessment from the FDA before filing a request for a weekly entry with the CBP.  The preliminary admissibility assessments are for the purpose of FDA reviewing whether the product is a good candidate for WEF, based on compliance with FDA-administered regulatory requirements and other factors relevant to FDA’s admissibility review.  This CPG describes what information the FDA needs to make a preliminary admissibility assessment.  

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities.  Instead, a guidance describes our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in FDA guidance means that something is suggested or recommended, but not required.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-3904.

Back to Top